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Case Report
Progression of Impending Central Retinal Vein Occlusion to 
the Ischemic Variant Following Intravitreal Bevacizumab
Na Rae Kim, Hee Seung Chin
Department of Ophthalmology, Inha University School of Medicine, Incheon, Korea
A 60-year-old woman who had experienced two episodes of amaurosis fugax in her right eye presented with vision 
loss. Two weeks earlier, at a private clinic, she was diagnosed with impending central retinal vein occlusion (CRVO) 
of the right eye and received an intravitreal injection of bevacizumab. Two weeks after this injection she was diag-
nosed with ischemic CRVO. At 11-weeks post-presentation, extremely ischemic features were observed with fluo-
rescein angiographic findings of severe vascular attenuation and extensive retinal capillary obliteration. At 
22-weeks post-presentation she was diagnosed with neovascular glaucoma; she experienced no visual improve-
ment over the following several months. 
Key Words: Bevacizumab, Central retinal vein occlusion
ⓒ2010 The Korean Ophthalmological Society
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses
/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Received: October 11, 2008     Accepted: May 3, 2010
Reprint requests to Hee Seung Chin. Department of Ophthalmology, Inha 
University Hospital, #7-206, Shinheung-dong, Jung-gu, Incheon 400-700, 
Korea. Tel: 82-32-890-2400, Fax: 82-32-890-2403, E-mail: hschin@inha.ac.kr
We report a case of ischemic central retinal vein occlusion 
(CRVO) in a patient who initially had impending CRVO and 
who was subsequently treated with intravitreal bevacizumab.
Case Report
A 60-year-old woman with a history of normal tension 
glaucoma presented because of vision loss in her right 
eye. Four weeks prior to her first visit to our hospital she 
had noted a sudden blurring over the entire visual field 
of her right eye. This lasted for approximately ten minutes 
and then fully recovered; eight days later, she experienced 
exactly the same phenomenon. Her previous clinical his-
tory was only significant for chronic hepatitis B. She did 
not have hypertension, diabetes mellitus, or hyperlipidemia.
She visited a private clinic on November 1, 2006. On 
examination, mild dilatation and tortuosity of the retinal 
veins, some intraretinal hemorrhages at the posterior pole, 
and a slightly swollen optic disc with small hemorrhages 
at the disc margin were found in her right eye (Fig. 1A). 
Her best corrected visual acuity (BCVA) was 20/20, and 
her intraocular pressure (IOP) was 12 mmHg. Fluorescein 
angiography (FAG) revealed normal choroidal filling and 
slightly delayed filling of the central retinal vein without 
capillary nonperfusion. The left eye was normal. She was 
diagnosed with impending CRVO and underwent a trial 
of intravitreal bevacizumab (2.5 mg in 0.1 mL) in an at-
tempt to improve the vascular stasis.
She was referred to our hospital two weeks after the 
bevacizumab injection, on November 13. Her BCVA was 
20/80, and the IOP was normal in her right eye. Fundus 
examination revealed numerous retinal hemorrhages in 
four quadrants, dilated and tortuous retinal veins, and severe 
disc swelling. Newly developed macular edema and cotton- 
wool spots were observed (Fig. 1B). FAG revealed normal 
choroidal circulation, a marked delay in arteriovenous 
transit time, and extensive areas of capillary nonperfusion. 
Optical coherence tomography revealed increased retinal 
thickness in the macular area. Electroretinography revealed 
decreased b-wave amplitude, but a normal a-wave. We 
diagnosed ischemic CRVO and continued to observe the 
patient without additional treatment. Laboratory data were 
unremarkable, including hemoglobin, platelet count, white 
cell count, electrolytes, and lipid profile. Additional ex-
aminations were subsequently performed; inflammatory 
markers and plasma viscosity were unremarkable. 
At three-weeks post-presentation, on November 20, 
the patient noted a significant decrease in visual acuity; 
her BCVA had declined to counting fingers. A slit lamp 
examination showed a relative afferent pupillary defect. At 
six-weeks post-presentation, on December 15, her BCVA 
was unchanged and her IOP was 14 mmHg. A fundus ex-Korean J Ophthalmol Vol.24, No.3, 2010
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Fig. 1. The right eye at presentation and at two- and 11-weeks post-presentation. (A) Dilated and tortuous retinal veins, some intraretinal hem-
orrhages at the posterior pole, and a slightly swollen optic disc were found in the right eye at presentation. (B) At two-weeks post-presentation, 
an ophthalmoscopic examination revealed an increase in intraretinal hemorrhages, more severe disc swelling, macular edema, and newly de-
veloped cotton-wool spots. (C) At 11-weeks post-presentation, an ophthalmoscopic examination revealed whitening of the posterior pole, vas-
cular compromise with severe attenuation, and optic disc pallor. (D) Midphase fluorescein angiography at 11-weeks post-presentation revealed 
extensive retinal capillary obliteration and severe attenuation of the retinal vessels.
amination revealed reductions in retinal hemorrhage and 
cotton-wool spots, moderate macular edema, and a somewhat 
sclerotic retinal vasculature. She received a prescription 
for aspirin 325 mg/day (acetylsalicylic acid). FAG was 
not performed on this occasion.  
The patient was observed for another five weeks. At 
11-weeks post-presentation, on January 22, her BCVA 
was counting fingers and her IOP was 14 mmHg. A slit 
lamp examination showed a rubeosis iridis. An oph-
thalmoscopic examination revealed opacification of the pos-
terior pole, severe attenuation of the retinal vessels, and 
optic disc pallor. The macular edema had nearly resolved 
(Fig. 1C). Serial FAG revealed severe attenuation of the 
retinal vessels, extensive retinal capillary obliteration, and 
late staining of the optic disc, suggesting an aggravation 
to the extremely ischemic form (Fig. 1D). Magnetic reso-
nance angiography showed no significant stenosis in the 
ipsilateral carotid artery (Fig. 2). Her right eye was im-
mediately treated with panretinal photocoagulation.
On March 5, at 22-weeks post-presentation, the patient 
developed painful neovascular glaucoma, refractory to 
topically administered IOP reducing agents. Her visual 
acuity had declined to hand movements, and her IOP was 
65 mmHg. Considerable iris neovascularization was evident, NR Kim, et al. Impending Central Retinal Vein Occlusion to the Ischemic Variant
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Fig. 2. Magnetic resonance angiography. 
The ipsilateral internal carotid artery was 
perfused without significant stenosis (white 
arrow).
and a slit-lamp examination revealed signs of inflammation, 
including mutton fat keratic precipitates, aqueous flare, 
and posterior synechiae. The patient was treated with pre-
dnisolone acetate four times a day, 1% atropine twice a 
day, and topical antiglaucoma agents. Despite maximal 
antiglaucoma medication, her right eye showed no visual 
recovery and her IOP remained uncontrolled. 
Discussion
We report a case of ischemic CRVO that initially presented 
as impending CRVO. Impending CRVO is an uncommon 
condition, which may resolve or progress to complete ob-
struction [1]. Our patient experienced recurrent amaurosis 
fugax in the setting of slightly dilated and tortuous retinal 
veins and scattered flame-shaped hemorrhages as signs of 
future CRVO that became ophthalmoscopically evident 
within four weeks of the onset of symptoms. 
The patient was given one intravitreal injection of bev-
acizumab (2.5 mg) prior to referral. Three weeks after 
this injection, her BCVA abruptly decreased to counting 
fingers. It is difficult to assess the exact effect of intra-
vitreal bevacizumab on her condition. Regarding the drug 
itself, vascular endothelial growth factor (VEGF) is 
known to have a neurotrophic effect, and blockage of all 
VEGF isoforms by bevacizumab may create toxic effects 
[2]. Neuronal tissue, including the neurosensory retina, 
may be vulnerable to complete VEGF inhibition, especially 
in the presence of a disease like CRVO. A recent case report 
of ischemic CRVO which progressed from nonischemic 
CRVO following intravitreal bevacizumab injection
  sup-
ports this hypothesis [3]. 
However, the effects of bevacizumab must be in-
terpreted cautiously in this case.
  Although the natural 
course of impending CRVO is not well established, a natural 
progression to ischemic CRVO is highly probable. Moreover, 
our patient had normal tension glaucoma that may have 
facilitated the CRVO. Further investigation regarding 
possible negative effects of intravitreal bevacizumab in 
ischemic conditions is needed.
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